BDNF and neoplasm: In addition, AA patient-derived prostatic epithelial cell line E006AA responds more aggressively to BDNF ligand than Caucasian tumor-derived LNCaP and C4-2B cells in vitro, and an antagonist to the BDNF tyrosine kinase receptor type 2 (TrkB) reduces the protumorigenic effects AA CAFs to a much greater extent than those of Caucasian CAFs [403].